GELSOMINO, FRANCESCO
GELSOMINO, FRANCESCO
DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE
Collaboratori
18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results
2016-01-01 G Polverari, V Ambrosini, F Gelsomino, S Diodato, F Ceci, F Sperandi, A Ardizzoni, S Fanti
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience
2020-01-01 Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F.
Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding
2018-01-01 Dall'Olio, Filippo Gustavo; Sperandi, Francesca; Rihawi, Karim; Gargiulo, Mauro; Melotti, Barbara; Brocchi, Stefano; Gelsomino, Francesco*; Ardizzoni, Andrea
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial)
2020-01-01 Gelsomino F.; Lamberti G.; Tiseo M.; Rocco D.; Pasello G.; Cecere F.L.; Chella A.; Grilli G.; Mandruzzato M.; Tognetto M.; Garassino M.C.; Macerelli M.; Novello S.; Roila F.; Colantonio I.; Grossi F.; Fiorentino M.; Ardizzoni A.
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
2020-01-01 Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A.
A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event
2018-01-01 Gelsomino, Francesco*; Vitale, Giovanni; Ardizzoni, Andrea
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC
2019-01-01 Mazzaschi, Giulia; Facchinetti, Francesco; Missale, Gabriele; Canetti, Diana; Madeddu, Denise; Zecca, Alessandra; Veneziani, Michele; Gelsomino, Francesco; Goldoni, Matteo; Buti, Sebastiano; Bordi, Paola; Aversa, Franco; Ardizzoni, Andrea; Quaini, Federico; Tiseo, Marcello
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab
2018-01-01 Facchinetti, Francesco*; Veneziani, Michele; Buti, Sebastiano; Gelsomino, Francesco; Squadrilli, Anna; Bordi, Paola; Bersanelli, Melissa; Cosenza, Agnese; Ferri, Leonarda; Rapacchi, Elena; Mazzaschi, Giulia; Leonardi, Francesco; Quaini, Federico; Ardizzoni, Andrea; Missale, Gabriele; Tiseo, Marcello
Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC
2019-01-01 Francesco Gelsomino,Giancarlo Facchini, Maria Aurelia Barbera, Giuseppe Lamberti, Stefano Brocchi, Giuseppe Rossi, Andrea Ardizzoni
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer
2020-01-01 Parisi C.; Lamberti G.; Zompatori M.; Gelsomino F.; Salvagni S.; Sperandi F.; Ardizzoni A.
The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers
2019-01-01 Gelsomino, Francesco; Lamberti, Giuseppe; Parisi, Claudia; Casolari, Laura; Melotti, Barbara; Sperandi, Francesca; Ardizzoni, Andrea
IFN-γ and CD38 in Hyperprogressive Cancer Development
2021-01-01 Angelicola, Stefania; Ruzzi, Francesca; Landuzzi, Lorena; Scalambra, Laura; Gelsomino, Francesco; Ardizzoni, Andrea; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna
Immune-mediated cholangitis: is it always nivolumab’s fault?
2018-01-01 Gelsomino, Francesco*; Vitale, Giovanni; Ardizzoni, Andrea
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
2019-01-01 Cinausero M.; Laprovitera N.; Maglio G.D.; Gerratana L.; Riefolo M.; Macerelli M.; Fiorentino M.; Porcellini E.; Buoro V.; Gelsomino F.; Squadrilli A.; Fasola G.; Negrini M.; Tiseo M.; Ferracin M.; Ardizzoni A.
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
2020-01-01 Raschi E.; Gatti M.; Gelsomino F.; Ardizzoni A.; Poluzzi E.; De Ponti F.
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players?
2020-01-01 Lamberti G.; Sisi M.; Andrini E.; Palladini A.; Giunchi F.; Lollini P.-L.; Ardizzoni A.; Gelsomino F.
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event
2020-01-01 Lamberti G.; Gelsomino F.; Brocchi S.; Poerio A.; Melotti B.; Sperandi F.; Gargiulo M.; Borghi C.; Fiorentino M.; Ardizzoni A.
Next-generation technologies in predictive molecular pathology of lung cancers
2022-01-01 de Biase, Dario; Maloberti, Thais; De Leo, Antonio; Sanza, Viviana; Visani, Michela; Gruppioni, Elisa; Altimari, Annalisa; Grillini, Alessia; Gelsomino, Francesco; Ferrari, Marco; Ardizzoni, Andrea; Tallini, Giovanni
Nivolumab-induced cholangitic liver disease: A novel form of serious liver injury
2017-01-01 Gelsomino, F; Vitale, G.; D'Errico, A.; Bertuzzi, C.; Andreone, P.; Ardizzoni, A.
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report
2020-01-01 Gelsomino F.; Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Lamberti G.; Sperandi F.; Balacchi C.; Brocchi S.; Ardizzoni A.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| 18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results | G Polverari, V Ambrosini, F Gelsomino, S Diodato, F Ceci, F Sperandi, A Ardizzoni, S Fanti | 2016-01-01 | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | - | 4.02 Riassunto (Abstract) | - |
| Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience | Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F. | 2020-01-01 | EXPERT OPINION ON BIOLOGICAL THERAPY | - | 1.01 Articolo in rivista | - |
| Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding | Dall'Olio, Filippo Gustavo; Sperandi, Francesca; Rihawi, Karim; Gargiulo, Mauro; Melotti, Barbara; Brocchi, Stefano; Gelsomino, Francesco*; Ardizzoni, Andrea | 2018-01-01 | JOURNAL OF THORACIC ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) | Gelsomino F.; Lamberti G.; Tiseo M.; Rocco D.; Pasello G.; Cecere F.L.; Chella A.; Grilli G.; Mandruzzato M.; Tognetto M.; Garassino M.C.; Macerelli M.; Novello S.; Roila F.; Colantonio I.; Grossi F.; Fiorentino M.; Ardizzoni A. | 2020-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | Gelsomino_CHANCE_TAMO'20.pdf |
| Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma | Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A. | 2020-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event | Gelsomino, Francesco*; Vitale, Giovanni; Ardizzoni, Andrea | 2018-01-01 | INVESTIGATIONAL NEW DRUGS | - | 1.01 Articolo in rivista | - |
| The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC | Mazzaschi, Giulia; Facchinetti, Francesco; Missale, Gabriele; Canetti, Diana; Madeddu, Denise; Zecca, Alessandra; Veneziani, Michele; Gelsomino, Francesco; Goldoni, Matteo; Buti, Sebastiano; Bordi, Paola; Aversa, Franco; Ardizzoni, Andrea; Quaini, Federico; Tiseo, Marcello | 2019-01-01 | LUNG CANCER | - | 1.01 Articolo in rivista | - |
| Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab | Facchinetti, Francesco*; Veneziani, Michele; Buti, Sebastiano; Gelsomino, Francesco; Squadrilli, Anna; Bordi, Paola; Bersanelli, Melissa; Cosenza, Agnese; Ferri, Leonarda; Rapacchi, Elena; Mazzaschi, Giulia; Leonardi, Francesco; Quaini, Federico; Ardizzoni, Andrea; Missale, Gabriele; Tiseo, Marcello | 2018-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC | Francesco Gelsomino,Giancarlo Facchini, Maria Aurelia Barbera, Giuseppe Lamberti, Stefano Brocchi, Giuseppe Rossi, Andrea Ardizzoni | 2019-01-01 | JOURNAL OF THORACIC ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer | Parisi C.; Lamberti G.; Zompatori M.; Gelsomino F.; Salvagni S.; Sperandi F.; Ardizzoni A. | 2020-01-01 | JOURNAL FOR IMMUNOTHERAPY OF CANCER | - | 1.01 Articolo in rivista | Parisi_Cystic airspaces_JIC'20.pdf |
| The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers | Gelsomino, Francesco; Lamberti, Giuseppe; Parisi, Claudia; Casolari, Laura; Melotti, Barbara; Sperandi, Francesca; Ardizzoni, Andrea | 2019-01-01 | CANCER TREATMENT REVIEWS | - | 1.01 Articolo in rivista | - |
| IFN-γ and CD38 in Hyperprogressive Cancer Development | Angelicola, Stefania; Ruzzi, Francesca; Landuzzi, Lorena; Scalambra, Laura; Gelsomino, Francesco; Ardizzoni, Andrea; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna | 2021-01-01 | CANCERS | - | 1.01 Articolo in rivista | CD38 cancers-13-00309-v2.pdf |
| Immune-mediated cholangitis: is it always nivolumab’s fault? | Gelsomino, Francesco*; Vitale, Giovanni; Ardizzoni, Andrea | 2018-01-01 | CANCER IMMUNOLOGY, IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC | Cinausero M.; Laprovitera N.; Maglio G.D.; Gerratana L.; Riefolo M.; Macerelli M.; Fiorentino M.; Porcellini E.; Buoro V.; Gelsomino F.; Squadrilli A.; Fasola G.; Negrini M.; Tiseo M.; Ferracin M.; Ardizzoni A. | 2019-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | 2019_Immunotherapy.pdf |
| Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance | Raschi E.; Gatti M.; Gelsomino F.; Ardizzoni A.; Poluzzi E.; De Ponti F. | 2020-01-01 | TARGETED ONCOLOGY | - | 1.01 Articolo in rivista | ICI_Targeted_Oncology_2020.pdf; 11523_2020_738_MOESM1_ESM.pdf |
| The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? | Lamberti G.; Sisi M.; Andrini E.; Palladini A.; Giunchi F.; Lollini P.-L.; Ardizzoni A.; Gelsomino F. | 2020-01-01 | CANCERS | - | 1.01 Articolo in rivista | Lamberti_PDL1_cancers-12-03129.pdf |
| New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event | Lamberti G.; Gelsomino F.; Brocchi S.; Poerio A.; Melotti B.; Sperandi F.; Gargiulo M.; Borghi C.; Fiorentino M.; Ardizzoni A. | 2020-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | Lamberti_atheromatous plaque_TAMO'20.pdf |
| Next-generation technologies in predictive molecular pathology of lung cancers | de Biase, Dario; Maloberti, Thais; De Leo, Antonio; Sanza, Viviana; Visani, Michela; Gruppioni, Elisa; Altimari, Annalisa; Grillini, Alessia; Gelsomino, Francesco; Ferrari, Marco; Ardizzoni, Andrea; Tallini, Giovanni | 2022-01-01 | Journal of Xiangya Medicine | - | 1.01 Articolo in rivista | - |
| Nivolumab-induced cholangitic liver disease: A novel form of serious liver injury | Gelsomino, F; Vitale, G.; D'Errico, A.; Bertuzzi, C.; Andreone, P.; Ardizzoni, A. | 2017-01-01 | ANNALS OF ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report | Gelsomino F.; Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Lamberti G.; Sperandi F.; Balacchi C.; Brocchi S.; Ardizzoni A. | 2020-01-01 | CLINICAL LUNG CANCER | - | 1.01 Articolo in rivista | - |